AN2 Therapeutics reports FY2024 net loss $51.3M; Phase 3 epetraborole data expected 2Q25

AN2 Therapeutics, Inc.

Cash, equivalents, investments $88.6M at Dec 31, 2024; expected to fund operations through 2027.
FY2024 net loss $51.3M vs $64.7M prior year; Q4 net loss $7.5M vs $16.9M.
Phase 3 topline data for epetraborole in treatment-refractory MAC lung disease due 2Q25.
Phase 1 trial of AN2-502998 for Chagas disease to start mid-2025 in healthy volunteers.
First oncology candidate from boron chemistry platform on track to advance in 2H25.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.